Heena Sharma Blog

  BDR Pharmaceuticals on Wednesday said it has launched the generic version ofLenvatinib drug for the treatmentof various types of cancers in India. The generic version of the drug has been launched under the brand name 'Bdfoie' in the country. Thecapsules are usedfor the treatment of differentiated thyroid cancer, advanced liver cancer and advanced kidney cancer,BDR Pharma said in a statement. The results of clinical trials showed encouraging results with safety and efficacy on patients with aggressive tumours, it added. The drug is priced at Rs 1,620 (4 mg) and Rs 2,970 (10 mg) for a pack of 10 capsules,the statement said. "By launching cost-effective therapy options we want to mitigate the challenges faced by Indian patients in seeking access to treatment and finding a timely cure for life threatening diseases,"BDR Pharmaceuticals CMDDharmesh Shah said. Read More

A pair of Harvard-trained American oncologists, backed by Hong Kong billionaire Li Ka-shing, are attempting to harness technology to revamp cancer care . They’re taking some of their earliest steps in China -- cancer’s ground zero. China has the world’s largest number of cancer patients, yet specialized treatment is in such short supply that patients must often travel long distances to top hospitals, living in dilapidated housing for months for short oncologist visits. That problem has begun drawing the attention of big name investors, and Li, one of Asia’s richest men, in 2015 became the first funder for the physicians’ startup, called Driver. Other investors joined, and now backed with $90 million, the firm is developing technology to give cancer patients more control over their care. It begins formally signing up patients in China and the U.S. this week, after a 17-month trial run with several hundred people. Read Complete Article